Posted by Michael Wonder on 29 Dec 2023
Medytox submits BLA for non-animal-derived liquid BTX formulation in US
28 December 2023 - Medytox said it has submitted a biologics license application to the US FDA for MT10109L, a non-animal derived liquid botulinum toxin formulation indicated for improving moderate to severe frown lines and crow's feet.
The submission follows Medytox's completion of five large-scale global Phase 3 clinical trials of MT10109L in February, involving 1,300 patients in the US, Canada, and European medical institutions.
